Erythroid cell patterns in neoplasms show distinct genomic profile and poor venetoclax response, new research suggests.

Shorter venetoclax durations in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) yielded comparable survival outcomes in a new study, challenging treatment norms ...

Rodriguez-Sevilla JJ, Ganan-Gomez I, Ma F, et al. Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes.

Updated data from the BEXMAB study reveals a significant increase in complete remission rates for patients with high-risk ...

One patient assigned to ibrutinib-venetoclax developed myelodysplastic syndrome / acute myeloid leukemia (AML), as did eight patients assigned to FCR.

And I think we'll get into, you know, the probably greatest unmet need is, once we do fail HMA-based therapy, particularly for higher risk myelodysplastic syndrome patients, there's really nothing.

AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival.

Source Reference: Bataller A, et al "Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre ...

The study evaluated a combination therapy involving its blockbuster cancer drug Venclexta (venetoclax) in newly diagnosed patients with higher-risk myelodysplastic syndrome (MDS).

And this was in all-comer, lower-risk, myelodysplastic syndrome. So, we anticipate that there will be a label change, in the near future, supporting a frontline treatment option.

First-line therapy was hypomethylating agent (HMA) monotherapy, lenalidomide, and venetoclax (20, 2, and 2 percent, respectively); the remaining patients were treated with supportive care.

Phase 1b/2 Study of Lisaftoclax (APG-2575) Combined with Azacitidine (AZA) in Patients with Treatment-Naïve or Prior Venetoclax-Exposed Myeloid Malignancies Abstract #: 6505 Format: Oral Presentation ...